Emyria Ltd has released a press release.
Emyria Secures Ethics Endorsement for MDMA AP Application
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Emyria
- Emyria hails strong growth in clinical billings
- September 2023 Quarterly Activities Report and Appendix 4C
- Health Canada Approval Received for MDMA Import
- Emyria's Clinic Achieves Key MDMA-AT Dosing Milestone
- Completion of Entitlement Offer
Later from Emyria
- Board Changes and Executive Restructuring
- Emyria Specialist Granted Authorised Prescriber Status
- Emyria Receives $2.5M R&D Tax Incentive Refund
- December 2023 Quarterly Activities Report and Appendix 4C
- Response to ASX Aware Query
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria